Fens Tanja, Boer Pieter T de, Puijenbroek Eugène P van, Postma Maarten J
Department of PharmacoTherapy, Epidemiology & -Economics (PTE2), Groningen Research Institute of Pharmacy, University of Groningen, 9713 AV Groningen, The Netherlands.
Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
Vaccines (Basel). 2021 Feb 2;9(2):111. doi: 10.3390/vaccines9020111.
(1) Background: Vaccines for seasonal influenza are a good preventive and cost-effective strategy. However, it is unknown and these economic evaluations include the adverse events following immunization (AEFI), and what the impact of such inclusion is on the health economic outcomes. (2) Methods: We searched the literature, up to January 2020, to identify economic evaluations of seasonal influenza vaccines that considered AEFIs. The review protocol was published in PROSPERO (CDR42017058523). (3) Results: A total of 52 economic evaluations considered AEFI-related parameters in their analyses, reflecting 16% of the economic evaluations on seasonal influenza vaccines in the initial study selection. Most studies used the societal perspective (64%) and evaluated vaccination of children (37%). Where considered, studies included direct medical costs of AEFIs (90%), indirect costs (27%), and disutilities/quality-adjusted life years loss due to AEFIs (37%). The majority of these studies accounted for the effects of the costs of AEFI on cost-effectiveness for Guillain-Barré syndrome. In those papers allowing cost share estimation, direct medical cost of AFEIs was less than 2% of total direct costs. (4) Conclusions: Although the overall impact of AEFIs on the cost-effectiveness outcomes was found to be low, we urge their inclusion in economic evaluations of seasonal influenza vaccines to reflect comprehensive reports for the decision makers and end-users of the vaccination strategies.
(1) 背景：季节性流感疫苗是一种有效的预防措施且具有成本效益。然而，尚不清楚这些经济评估是否涵盖免疫接种后的不良事件（AEFI），以及这种纳入对健康经济结果有何影响。(2) 方法：我们检索了截至2020年1月的文献，以确定考虑AEFI的季节性流感疫苗经济评估。该综述方案已发表在PROSPERO（CDR42017058523）上。(3) 结果：共有52项经济评估在分析中考虑了与AEFI相关的参数，占初始研究选择中季节性流感疫苗经济评估的16%。大多数研究采用社会视角（64%），并评估了儿童接种疫苗情况（37%）。在考虑的情况下，研究包括AEFI的直接医疗成本（90%）、间接成本（27%）以及因AEFI导致的效用损失/质量调整生命年损失（37%）。这些研究中的大多数考虑了AEFI成本对吉兰 - 巴雷综合征成本效益的影响。在那些允许估计成本分担的论文中，AEFIs的直接医疗成本不到总直接成本的2%。(4) 结论：尽管发现AEFI对成本效益结果的总体影响较低，但我们敦促在季节性流感疫苗的经济评估中纳入这些因素，以便为疫苗接种策略的决策者和最终用户提供全面的报告。
